Development of novel Albendazole oral microparticles for the treatment of Cystic Echinococcocis

PICCIRILLI, G.N.; MAMPRIN, M.E.; SALOMÓN, C.J.; LAMAS, M.C.

Antalya

Simposio; 18th International Symposium on Microencapsulation; 2011

Albendazole (ABZ), a benzimidazole methylcarbamate, is a broad spectrum antiparasitic agent and the first chosen drug in human and animals for the treatment of hydatid disease. This drug is used for the prevention and treatment of non-surgical cases and as a supplementary medical care prior and post-surgery. It is well known that the absorption of ABZ after the oral administration is limited and erratic due to its low aqueous solubility (0.2 mg/mL in water at 25ºC) being an important disadvantage for the treatments of systemic infection. Microencapsulation is one of the most frequently chosen methodologies to produce dosage forms improving the drug bioavailability and also to regulate de drug release after the oral administration. The objective of this work was to obtain biocompatible microparticles to administrate ABZ by the oral route optimizing the bioavailability. The microencapsulation polymer propose for this study was chitosan (CH), a biodegradable cationic polysaccharide obtained by the deacetylation of chitin. In the current work, microspheres were prepared by spray drying method, based in an ionic gelation process with an anionic surfactant: sodium lauryl sulphate (SLS).